NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)

National Comprehensive Cancer Network® (NCCN®) Guidelines® recommend inotuzumab ozogamicin as a treatment option for adults with relapsed or refractory B-cell precursor ALL1

  • BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor ALL2

ALL=acute lymphoblastic leukemia; Ph=Philadelphia chromosome; TKI=tyrosine kinase inhibitor.

References
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 26, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.
  2. BESPONSA Prescribing Information. New York, NY: Pfizer Inc.